Verve Therapeutics (NASDAQ:VERV - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.14, Zacks reports. The company had revenue of $13.08 million for the quarter, compared to analyst estimates of $3.94 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%.
Verve Therapeutics Trading Down 2.9 %
Shares of NASDAQ VERV traded down $0.19 during midday trading on Monday, reaching $6.15. The company's stock had a trading volume of 974,224 shares, compared to its average volume of 1,528,181. Verve Therapeutics has a one year low of $4.30 and a one year high of $16.50. The company has a market cap of $520.26 million, a price-to-earnings ratio of -2.52 and a beta of 1.74. The company has a 50 day moving average price of $6.90 and a 200 day moving average price of $6.02.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on VERV shares. Canaccord Genuity Group lifted their price objective on shares of Verve Therapeutics from $29.00 to $32.00 and gave the company a "buy" rating in a research note on Wednesday, November 6th. William Blair reiterated an "outperform" rating on shares of Verve Therapeutics in a report on Friday, February 21st. HC Wainwright boosted their target price on Verve Therapeutics from $14.00 to $15.00 and gave the stock a "buy" rating in a report on Friday. Finally, Royal Bank of Canada decreased their price target on Verve Therapeutics from $20.00 to $17.00 and set an "outperform" rating for the company in a research note on Wednesday, November 6th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $26.00.
Check Out Our Latest Analysis on VERV
About Verve Therapeutics
(
Get Free Report)
Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.
Recommended Stories
Before you consider Verve Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verve Therapeutics wasn't on the list.
While Verve Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
